Literature DB >> 29900982

Longitudinal Myelitis of a Neuro-Behçet Patient.

Qi Tang1, Jing Tian1.   

Abstract

Behçet's disease is a chronic, relapsing inflammatory disorder of unknown etiology. Neuro-Behçet's disease (NBD) occurs in approximately 5 to 49% of patients with Behçet's disease. Spinal cord involvement is very rare in NBD. In this article, we report a 22-year-old male patient of NBD with longitudinal myelitis involving the entire spinal cord. Patient was admitted with one-week of headache, vomiting, and urinary incontinence. Before admission, he felt motor weakness for two years and had noticed recurrent genital and oral ulcers with a frequency of more than three episodes per year for five years. T2-weighted spinal magnetic resonance images showed hyperintensities within the entire spinal cord. He was diagnosed as NBD with longitudinal myelitis. Intravenous methylprednisolone (120 mg/day) was administered for three days, followed by an oral administration of prednisolone (45 mg/day). In conjunction with the steroid therapy, intravenous cyclophosphamide (0.4 g/week) was administered twice. Rapid improvements were detected after receiving treatments for half a month. NBD associated longitudinal myelitis is really rare. This case provided important implications for the diagnosis and treatment of longitudinal myelitis in NBD patients.

Entities:  

Keywords:  Corticosteroid; cyclophosphamide; longitudinal myelitis; magnetic resonance imaging; neuro-Behçet’s disease

Year:  2015        PMID: 29900982      PMCID: PMC5827873          DOI: 10.5606/ArchRheumatol.2016.5441

Source DB:  PubMed          Journal:  Arch Rheumatol        ISSN: 2148-5046            Impact factor:   1.472


  11 in total

Review 1.  Behçet's disease.

Authors:  T Sakane; M Takeno; N Suzuki; G Inaba
Journal:  N Engl J Med       Date:  1999-10-21       Impact factor: 91.245

2.  Neurological complications in Behçet's syndrome.

Authors:  D Kidd; A Steuer; A M Denman; P Rudge
Journal:  Brain       Date:  1999-11       Impact factor: 13.501

3.  Successful treatment of refractory neuro-Behcet's disease with infliximab: a case report to show its efficacy by magnetic resonance imaging, transcranial magnetic stimulation and cytokine profile.

Authors:  K Fujikawa; K Aratake; A Kawakami; T Aramaki; N Iwanaga; Y Izumi; K Arima; M Kamachi; M Tamai; M Huang; H Nakamura; Y Nishiura; T Origuchi; H Ida; K Eguchi
Journal:  Ann Rheum Dis       Date:  2007-01       Impact factor: 19.103

Review 4.  Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease.

Authors: 
Journal:  Lancet       Date:  1990-05-05       Impact factor: 79.321

Review 5.  Infliximab monotherapy in neuro-Behçet's disease: four year follow-up in a long-standing case resistant to conventional therapies.

Authors:  Alfonso Fasano; Magda D'Agostino; Giacomo Caldarola; Claudio Feliciani; Clara De Simone
Journal:  J Neuroimmunol       Date:  2011-09-10       Impact factor: 3.478

6.  Teaching NeuroImages: longitudinally extensive transverse myelitis in neuro-Behcet disease.

Authors:  Deirdre Graham; Allan McCarthy; Eoin Kavanagh; Killian O'Rourke; Timothy Lynch
Journal:  Neurology       Date:  2013-04-30       Impact factor: 9.910

Review 7.  Longitudinal extensive transverse myelitis--it's not all neuromyelitis optica.

Authors:  Corinna Trebst; Peter Raab; Elke Verena Voss; Paulus Rommer; Mazen Abu-Mugheisib; Uwe K Zettl; Martin Stangel
Journal:  Nat Rev Neurol       Date:  2011-11-01       Impact factor: 42.937

Review 8.  Longitudinally extensive transverse myelitis in systemic lupus erythematosus: case report and review of the literature.

Authors:  Raffaele Nardone; Ryan T Fitzgerald; Ariel Bailey; Giulio Zuccoli
Journal:  Clin Neurol Neurosurg       Date:  2014-12-13       Impact factor: 1.876

Review 9.  Treatment of neuro-Behçet's disease: an update.

Authors:  Afshin Borhani Haghighi
Journal:  Expert Rev Neurother       Date:  2009-04       Impact factor: 4.618

Review 10.  Neuro-Behçet's disease: epidemiology, clinical characteristics, and management.

Authors:  Adnan Al-Araji; Desmond P Kidd
Journal:  Lancet Neurol       Date:  2009-02       Impact factor: 44.182

View more
  1 in total

Review 1.  Magnetic resonance imaging in immune-mediated myelopathies.

Authors:  M J Wendebourg; S Nagy; T Derfuss; K Parmar; R Schlaeger
Journal:  J Neurol       Date:  2019-01-29       Impact factor: 4.849

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.